116 related articles for article (PubMed ID: 30990915)
1. Colorectal large-cell neuroendocrine carcinoma with lymphoid stroma: further evidence confirming a unique subtype associated with MLH1/PMS2 loss, BRAF mutation, Epstein-Barr virus negativity, and the possibility of a better prognosis.
Chetty R; Capo-Chichi JM; Serra S
Histopathology; 2019 Aug; 75(2):247-253. PubMed ID: 30990915
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.
Hu H; Chang DT; Nikiforova MN; Kuan SF; Pai RK
Am J Surg Pathol; 2013 Nov; 37(11):1660-70. PubMed ID: 23887157
[TBL] [Abstract][Full Text] [Related]
3. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
5. Paranuclear dot-like pancytokeratin positivity and MLH1/PMS2 loss in large cell neuroendocrine carcinoma of the endometrium.
Chougule A; Garg R; Jain V
Pathology; 2016 Dec; 48(7):736-739. PubMed ID: 27780606
[No Abstract] [Full Text] [Related]
6. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
7. Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status.
Thompson ED; Stelow EB; Mills SE; Westra WH; Bishop JA
Am J Surg Pathol; 2016 Apr; 40(4):471-8. PubMed ID: 26735857
[TBL] [Abstract][Full Text] [Related]
8. MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF
Fennell LJ; Jamieson S; McKeone D; Corish T; Rohdmann M; Furner T; Bettington M; Liu C; Kawamata F; Bond C; Van De Pols J; Leggett B; Whitehall V
BMC Cancer; 2018 Jan; 18(1):35. PubMed ID: 29304767
[TBL] [Abstract][Full Text] [Related]
9. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer.
Park JH; Kim EK; Kim YH; Kim JH; Bae YS; Lee YC; Cheong JH; Noh SH; Kim H
Gastric Cancer; 2016 Oct; 19(4):1041-1051. PubMed ID: 26573601
[TBL] [Abstract][Full Text] [Related]
11. Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.
Soliman ML; Tiwari A; Zhao Q
World J Gastroenterol; 2017 Feb; 23(6):1106-1112. PubMed ID: 28246485
[TBL] [Abstract][Full Text] [Related]
12. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations.
Rekhtman N; Pietanza CM; Sabari J; Montecalvo J; Wang H; Habeeb O; Kadota K; Adusumilli P; Rudin CM; Ladanyi M; Travis WD; Joubert P
Mod Pathol; 2018 Jan; 31(1):111-121. PubMed ID: 28884744
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency.
Nakano K; Yamamoto H; Fujiwara M; Koga Y; Tsuruta S; Ihara E; Oki E; Nakamura M; Ogawa Y; Oda Y
Am J Surg Pathol; 2018 Feb; 42(2):172-182. PubMed ID: 28877066
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
16. Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
Woischke C; Jung P; Jung A; Kumbrink J; Eisenlohr S; Auernhammer CJ; Vieth M; Kirchner T; Neumann J
J Pathol Clin Res; 2021 Jan; 7(1):75-85. PubMed ID: 33197299
[TBL] [Abstract][Full Text] [Related]
17. Long Survival and Prolonged Remission after Surgery and Chemotherapy in a Metastatic Mismatch Repair Deficient Pancreatic Neuroendocrine Carcinoma with MLH1/PMS2 Immunodeficiency and Minimal Microsatellite Shift.
Vanoli A; Perfetti V; Furlan D; Neri G; Viglio A; Sessa F; Martino M; Di Sabatino A; Solcia E; La Rosa S
Endocr Pathol; 2020 Dec; 31(4):411-417. PubMed ID: 32388775
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
[No Abstract] [Full Text] [Related]
19. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
[TBL] [Abstract][Full Text] [Related]
20. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
